"Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Descriptor ID |
D011658
|
| MeSH Number(s) |
C08.381.765
|
| Concept/Terms |
Pulmonary Fibrosis- Pulmonary Fibrosis
- Pulmonary Fibroses
- Fibroses, Pulmonary
- Fibrosis, Pulmonary
Alveolitis, Fibrosing- Alveolitis, Fibrosing
- Alveolitides, Fibrosing
- Fibrosing Alveolitides
- Fibrosing Alveolitis
- Hamman-Rich Syndrome
- Hamman Rich Syndrome
- Syndrome, Hamman-Rich
|
Below are MeSH descriptors whose meaning is more general than "Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Pulmonary Fibrosis".
This graph shows the total number of publications written about "Pulmonary Fibrosis" by people in this website by year, and whether "Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 1 | 3 |
| 2015 | 8 | 1 | 9 |
| 2016 | 5 | 2 | 7 |
| 2017 | 2 | 2 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 5 | 2 | 7 |
| 2020 | 5 | 0 | 5 |
| 2021 | 6 | 0 | 6 |
| 2022 | 2 | 0 | 2 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pulmonary Fibrosis" by people in Profiles.
-
Telltale Signs of Lower Lobe Pulmonary Fibrosis. Ann Am Thorac Soc. 2024 Oct; 21(10):1458-1460.
-
Blocking antibodies against integrin-a3, -aM, and -aMß2 de-differentiate myofibroblasts, and improve lung fibrosis and kidney fibrosis. Sci Rep. 2024 09 16; 14(1):21623.
-
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):392-400.
-
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):401-423.
-
Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis. Ann Am Thorac Soc. 2024 Aug; 21(8):1156-1165.
-
Local, Quantitative Morphometry of Fibroproliferative Lung Injury Using Laminin. Am J Respir Cell Mol Biol. 2024 Jul; 71(1):23-29.
-
Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2024 Jan; 63(1).
-
Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis. Ann Am Thorac Soc. 2023 12; 20(12):1683-1693.
-
Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. Nat Commun. 2023 03 17; 14(1):1489.
-
Upper Lobe Pulmonary Fibrosis: An Atypical Location for Pulmonary Fibrosis. Ann Am Thorac Soc. 2023 03; 20(3):470-472.